
Monte Rosa Therapeutics (GLUE) announced the presentation of preclinical data showing that MRT-8102, a NEK7-directed MGD, inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics | 8.59 | -4.44 | -34.10% |
| Name | Price | % Change | |
|---|---|---|---|
| $8.59 | -34.10% |

Monte Rosa Therapeutics (GLUE) announced the presentation of preclinical data showing that MRT-8102, a NEK7-directed MGD, inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Monte Rosa Therapeutics today and set a price target of $25.00. Mitchell Kapoor’s Buy rating is based on Monte Rosa’s

Jefferies analyst Faisal Khurshid lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $15 from $25 and keeps a Buy rating on the shares. There were no updates

“The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for

Monte Rosa Therapeutics (GLUE) announced that its collaborator Novartis (NVS) has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 in people living with active moderate to

UBS assumed coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and price target of $19, up from $17. The firm believes the company’s MRT-8102, a first-in-class oral NEK7

Monte Rosa Therapeutics ( ($GLUE) ) just unveiled an update. On October 1, 2026, Monte Rosa Therapeutics reported positive topline data from its GFORCE-1 Phase 1 study of MRT-8102 in

Monte Rosa Therapeutics (GLUE) announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NEK7/NLRP3

H.C. Wainwright initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $25 price target The company is undervalued at a $565M enterprise value given its two wholly-owned

S&P 500 fell for the third straight day as an investor enthusiasm over the possibility of a less aggressive Federal Reserve following today’s benign PCE inflation data was reversed into
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Assigned | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Initiated | Oct 12, 2026 | ||||
| buy | Reiterated | Oct 2, 2026 | ||||
| buy | Reiterated | Aug 10, 2026 | ||||
| buy | Reiterated | May 7, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 18, 2027TBA | $761.36M | $-0.21 | $35.66M | 0.67 | -5.21 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.